US Marijuana PTSD Study

 

Placebo-Controlled, Triple-Blind, Randomized Crossover Pilot Study of the Safety and Efficacy of Five Different Potencies of Smoked or Vaporized Marijuana in 50 Veterans with Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)

Clinical Investigator: Sue Sisley, M.D.

This study will look at whether smoking or vaporizing marijuana can help reduce PTSD symptoms in fifty veterans with posttraumatic stress disorder (PTSD). Participants can be men or women aged 18 or older with a diagnosis of PTSD that has not improved after they have tried either medication or psychotherapy.

Study Protocol: MJP-1 Protocol (3/9/2011)

On November 17, 2010, MAPS received an Investigational New Drug identification number for marijuana from the FDA.

On December 15, 2010, the FDA placed the study on full clinical hold.

On February 3, 2011, the FDA sent MAPS a letter outlining several issues relating to protocol design.

On February 9, 2011, the FDA and MAPS held a teleconference during which MAPS successfully addressed the FDA’s concerns, including the potential for diversion of marijuana used in the study.

On March 15, 2011, MAPS submitted the revised protocol incorporating the changes discussed on February 9 to the FDA.

On April 28, 2011, the revised protocol was accepted by the FDA, and submitted to the Department of Health and Human Services (HHS) to be reviewed by the National Institute on Drug Abuse (NIDA) and the Public Health Service (PHS).

On July 15, 2011, HHS informed MAPS that the NIDA/PHS review had been completed and that we should receive the report soon.

On September 16, 2011, HHS informed MAPS that the NIDA/PHS reviewers had unanimously rejected the protocol as currently designed. For a concise summary of the HHS review, see the September 16 HHS cover letter. For MAPS’ detailed, point-by-point response to the HHS review, see the annotated reviewer comments.

MAPS is now preparing a detailed response to the NIDA/PHS reviewers’ comments.

  1. PTSD treatment for Veterans found ineffective.

    Eli Lilly made $65 billion on the Zyprexa franchise.Lilly was fined $1.4 billion for Zyprexa fraud!
    The atypical antipsychotics (Zyprexa,Risperdal,Seroquel) are like a ‘synthetic’ Thorazine,only they cost ten times more than the old fashioned typical antipsychotics.
    These newer generation drugs still pack their list of side effects like diabetes for the user.All these drugs work as so called ‘major tranquilizers’.This can be a contradiction with PTSD suffers as we are hyper vigilant and feel uncomfortable with a drug that puts you to sleep and makes you sluggish.
    That’s why drugs like Zyprexa don’t work for PTSD survivors like myself.
    -Daniel Haszard FMI http://www.zyprexa-victims.com

  1. No trackbacks yet.

You must be logged in to post a comment.
%d bloggers like this: